Get the Stockscreener App
94.00
1.64%
1.52
After Hours:
94.00
Mirum Pharmaceuticals Inc stock is traded at $94.00, with a volume of 621.78K.
It is up +1.64% in the last 24 hours and up +6.29% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$92.48
Open:
$93.34
24h Volume:
621.78K
Relative Volume:
0.78
Market Cap:
$5.73B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-196.61
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
+0.72%
1M Performance:
+6.29%
6M Performance:
+33.31%
1Y Performance:
+127.55%
1-Day Range:
$92.13
$94.67
1-Week Range:
$90.00
$95.61
52-Week Range:
$40.00
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
94.00 | 5.64B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake - Stock Titan
Mirum’s brelovitug succeeds in Phase 2b HDV trial - TipRanks
Baird raises Mirum Pharmaceuticals stock price target on HDV data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in HDV – Key Efficacy and Safety Data Shared, Phase 3 and BLA Timeline Announced - Minichart
Mirum Pharmaceuticals Announces Primary Endpoint Met In Phase 2B Portion Of The Azure-1 Study - TradingView
Mirum’s hepatitis delta drug meets phase 2b study goals - Investing.com
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - The Joplin Globe
Mirum’s hepatitis delta drug meets phase 2b study goals By Investing.com - Investing.com Canada
Brelovitug shows high HDV response rates in Mirum (NASDAQ: MIRM) Phase 2b - Stock Titan
Executive pay, board elections headline Mirum (NASDAQ: MIRM) 2026 proxy - Stock Titan
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings? - qz.com
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Will Livmarli continue to aid Mirum's top line in Q1 earnings? - MSN
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Citizens Jmp Reiterates Market Outperform Rating for Mirum Pharmaceuticals (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals (MIRM) Stock: Why It Could Stabilize (Mini Selloff) 2026-04-20Institutional Flow - Cổng thông tin điện tử Tỉnh Sơn La
Mirum Pharmaceuticals 2026 Analysis: Revenue Growth & Pipeline MilestonesNews and Statistics - IndexBox
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term - AOL.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Eastern Progress
Mirum pharmaceuticals director Saira Ramasastry sells $193,800 in stock By Investing.com - Investing.com India
Mirum pharmaceuticals director Saira Ramasastry sells $193,800 in stock - Investing.com
Mirum (MIRM) director uses options, sells 2,000 pre-planned shares - Stock Titan
MIRM (NASDAQ: MIRM) files Rule 144: 2,000 shares via option exercise - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2026 - BioSpace
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ETF Watch: What are analysts price targets for Mirum Pharmaceuticals IncMarket Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Aug Movers: Does Mirum Pharmaceuticals Inc stock benefit from AI growthMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Prediction: Buying This Biotech Stock Today Could Set You Up for Life - Yahoo Finance
Tudor Investment Corp ET AL Takes $2.03 Million Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM) - The Globe and Mail
How Mirum Pharmaceuticals Inc. (MIRM) Affects Rotational Strategy Timing - Stock Traders Daily
Cantor Fitzgerald reiterates Mirum Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Bluejay Therapeutics 2025 Financials: Mirum Pharmaceuticals Merger, Liquidity, and Key Financial Statements - Minichart
Mirum (MIRM) details Bluejay deal and $268.5M PIPE financing - Stock Titan
Primary Sclerosing Cholangitis Market is expected to Hit US$ - openPR.com
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - MSN
Mirum (MIRM) Q1 2025 Earnings Call Transcript - AOL.com
MIRM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MIRM PE Ratio & Valuation, Is MIRM Overvalued - Intellectia AI
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history - Yahoo Finance UK
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report? - Eastern Progress
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last? - qz.com
Mirum Pharmaceuticals (MIRM) Rises 5.1%: Can This Upward Momentum Continue? - Bitget
Mirum Pharma (MIRM) Earnings Call Transcript - AOL.com
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
(MIRM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ramasastry Saira | Director |
Apr 15 '26 |
Sale |
96.90 |
2,000 |
193,800 |
0 |
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):